FRIDAY, Sept. 7 (HealthDay News) — A new gene-based dosing formula for the
anti-clotting drug warfarin should make it easier to prescribe the correct dose
of the blood thinner, researchers say.
Up to this point, doctors have had to engage in a trial-and-error process over
several weeks that left patients at risk of hemorrhaging from low doses or
developing blood clots with too-high doses.
"We already knew these genes affected warfarin dosing, but we didn’t know how to
use that information clinically," researcher Dr. Brian Gage, medical director of
Barnes-Jewish Hospital’s Blood Thinner Clinic, said in a prepared statement.
"But with this study, we’ve established a simple way to combine these genetic
factors with clinical factors in a dosing algorithm."
Gage and colleagues developed the formula based on study participants who had
undergone hip replacement or knee surgery. The study team focused on two genes,
VKORC1 and CYP2C9, which are known to affect the way warfarin operates inside
Using the new method, physicians head to a Web-based tool to calculate a
patient’s initial dosage more accurately…